Magnesium oxybate is one of four salt forms of the drug oxybate, combined in the prescription medication Xywav. It is not sold or used on its own. Instead, it’s mixed with calcium oxybate, potassium oxybate, and a small amount of sodium oxybate to create a lower-sodium version of an older narcolepsy drug. The active ingredient in all oxybate salts is gamma-hydroxybutyrate (GHB), a potent central nervous system depressant used to treat serious sleep disorders.
How It Fits Into Xywav
Each milliliter of Xywav contains 0.096 g of magnesium oxybate alongside 0.234 g of calcium oxybate, 0.13 g of potassium oxybate, and 0.04 g of sodium oxybate. Together, these salts deliver 0.413 g of the active oxybate compound per milliliter. The reason for using multiple mineral salts instead of sodium alone comes down to one thing: drastically cutting sodium intake.
The earlier version of this drug, Xyrem, used only sodium oxybate. At typical nightly doses (6 to 9 grams), Xyrem added 1,100 to 1,640 mg of sodium to a patient’s daily diet, a significant chunk of the recommended daily limit. Xywav’s mixed-salt formula, with magnesium oxybate as a key component, contains 92% less sodium: just 87 to 131 mg per night at the same dose range.
What Oxybate Does in the Body
Once you swallow Xywav, the mineral salts (magnesium, calcium, potassium, sodium) separate from the oxybate molecule. The oxybate is the part that produces the therapeutic effect. It acts as a central nervous system depressant, promoting deep, consolidated sleep. This is especially important for people with narcolepsy, whose sleep architecture is fragmented and shallow, leading to severe daytime symptoms.
The magnesium, calcium, and potassium released from the salts are simply absorbed by the body the way dietary minerals are. They don’t contribute meaningfully to the drug’s sleep-promoting action. Their role is structural: they allow the oxybate to be formulated as an oral solution without loading the body with excess sodium.
Conditions It Treats
Xywav is FDA-approved for three specific uses:
- Cataplexy in narcolepsy in patients 7 years and older. Cataplexy causes sudden, brief episodes of muscle weakness triggered by emotions like laughter or surprise.
- Excessive daytime sleepiness in narcolepsy in patients 7 years and older. This goes beyond ordinary tiredness. People with narcolepsy can fall asleep involuntarily during conversations, meals, or while driving.
- Idiopathic hypersomnia in adults, a condition where people sleep excessively (often 11 or more hours) yet still feel profoundly unrefreshed and struggle to wake up.
Xywav is classified as a Schedule III controlled substance, meaning it has recognized medical use but also potential for misuse and dependence.
Why Lower Sodium Matters
People with narcolepsy already face elevated risk for high blood pressure and cardiovascular disease. Adding over 1,000 mg of pharmaceutical sodium nightly on top of dietary sodium compounded that risk. Research has shown a linear relationship between sodium intake and blood pressure: every 1,000 mg increase in sodium is associated with a 6% to 17% rise in cardiovascular disease risk.
A study of 43 patients who switched from high-sodium oxybate (Xyrem) to the low-sodium formulation (Xywav) found meaningful results. Their median daily urinary sodium dropped by about 1,288 mg per day. Average 24-hour systolic blood pressure fell by 4.1 mm Hg, and office systolic readings dropped by 9.2 mm Hg. These reductions are comparable to, or even exceed, what people typically achieve through dietary salt-cutting alone. The FDA has stated that the reduced sodium burden of the low-sodium formulation provides greater safety and will be clinically meaningful in reducing cardiovascular complications for a substantial portion of patients.
How Patients Take It
Xywav is taken at night as a liquid, at least two hours after eating. For most adults with narcolepsy, the starting dose is 4.5 grams per night, split into two separate doses. The first dose is taken at bedtime while lying down. The second dose is taken 2.5 to 4 hours later, which means many patients set an alarm to wake up in the middle of the night for it. The dose is gradually increased each week until symptoms are adequately controlled, up to a maximum of 9 grams per night.
For idiopathic hypersomnia, some patients take a once-nightly dose instead, starting at 3 grams and increasing up to 6 grams. Pediatric dosing for narcolepsy is weight-based, starting lower and increasing more slowly.
Prescribing Restrictions
Because the active ingredient is GHB, Xywav is available only through a tightly controlled distribution program called REMS (Risk Evaluation and Mitigation Strategy). Both the prescribing doctor and the patient must enroll in this program. Doctors are required to screen patients for a history of substance abuse, breathing disorders, depression, and use of other sedating medications before writing a prescription. Patients receive counseling on the drug’s risks and complete a checklist with a pharmacist. You cannot fill this prescription at a regular pharmacy; it is dispensed through a centralized specialty pharmacy.
This level of oversight reflects the seriousness of the drug. Oxybate suppresses breathing and consciousness, and combining it with alcohol or other sedatives can be life-threatening. The controlled distribution system exists to reduce the risk of misuse and to ensure patients understand what they’re taking.